Press Releases

Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction today announced that it has completed first dosing of the re-started Phase I study.

Initiator Pharma A/S (“Initiator Pharma”) announced today, November 15, 2018, that the exercised series TO 1 warrants, whose subscription period ended on November 1, 2018, and the directed share issue, have now been registered with the Danish Companies Registration Office.

Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction today announced that it has signed an option agreement with Saniona AB, for a phase 2 ready drug candidate.

On November 1st, 2018, the exercise period for series TO 1 warrants in Initiator Pharma A/S (“Initiator Pharma”) ended. In total, 5.462.843warrants of series TO 1 were exercised, which means a subscription rate of 94,4 percent.In order for the company to receive the full financing intended with the exercise of warrants, the Board, with authorization from the 2018 Annual General Meeting, has decided on a directed share issue of 326.451 shares, corresponding to approx. SEK 0,7 million, to Wilhelm Risberg who has been consideration-free guarantee subscriber in the warrant exercise. Initiator Pharma is provided with approx. SEK 12.7 million before issue costs as a result of the warrant exercise and the directed share issue.

Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction today announced that it will continue the Phase Clinical trials with IPED2015 in the week of the 12thof November.

The subscription period for the series TO 1 warrants issued as part of Initiator Pharma A/S’s (“Initiator Pharma”) rights issue conducted during the spring of 2018 will continue until November 1, 2018. The last day for trading with the series TO 1 warrants is October 30, 2018. Holders of the series TO 1 warrants are entitled to subscribe for one new share for each warrant at a price of SEK 2.20 per share. If all of the series TO 1 warrants are exercised, 5,789,294 new shares are emitted, and Initiator Pharma is allocated approximately SEK 12.7 million before issue costs.

Today, October 11, 2018, the subscription period of the series TO 1 warrants in Initiator Pharma A/S (“Initiator Pharma”) begins. The series TO 1 warrants were emitted in conjunction with the rights issue that Initiator Pharma conducted during the spring of 2018. The subscription period will continue until November 1, 2018. For every warrant of series TO 1, holders are entitled to subscribe for a new share in Initiator Pharma at a price of SEK 2.20 per share. If all warrants of series TO 1 are exercised, 5,789,294 new shares are emitted, and Initiator Pharma is allocated approximately SEK 12.7 million before issue costs. The company also announces that the Board of directors, the executive management team and the main shareholders have, through subscription agreements, committed to exercise their respective warrants. In addition, the company has entered a guarantee commitment agreement of up to SEK 1.3 million with Wilhelm Risberg, equivalent to approximately 10 % of the total issue amount, provided that a Board decision is taken in case all warrants are not exercised. For the guarantee subscription, no compensation is disbursed.

Initiator Pharma A/S, a biotech company developing a novel treatment of erectile dysfunction, today announced that it has received approval for an amendment to the clinical trial protocol to the Medicines & Healthcare products Regulatory Agency, MHRA, UK as well as the Ethics Committee, EC.

Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction today announced that it has submitted an amendment to the clinical trial protocol to the Medicines & Healthcare products Regulatory Agency, MHRA, UK as well as the Ethics Committee, EC on the 21st of September.